Examining the impact of voluntary restricted distribution systems in the pharmaceutical supply chain :  hearing before the Subcommittee on Healthcare, Benefits, and Administrative Rules of the Committee on Oversight and Government Reform, House of Representatives, One Hundred Fifteenth Congress, first session, March 22, 2017. 

 - iii, 54 pages ;  24 cm 
<br/><br/> "Serial no. 115-33."  Shipping list no.: 2018-0099-M.  CRDP Program record. 
<br/><br/>Includes bibliographical references. 
<br/><br/><br/>Microfiche. <br/>[Washington, D.C.] : <br/>U.S. Government Printing Office, <br/>[2018] <br/>1 microfiche : negative. 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Pharmaceutical industry--Corrupt practices--United States.<br/>Pharmaceutical policy--United States.<br/>Generic drugs--Development--United States.<br/>Prescription pricing--United States.<br/>Competition--United States.<br/>Consumer protection--United States.
<br/><br/><label>Index Terms--Genre/Form: </label><br/>Legislative hearings.
<br/><br/><label>LC Class. No.: </label>KF27  / .O9435 2017c 
<br/><br/><label>GPO Item No.: </label>1016-B (MF) 
<br/><br/><label>Gov. Doc. Class. No.: </label>Y 4.G 74/7:115-33 
<br/><br/><label>Report. No.: </label>Serial no. 115-33 (United States. Congress. House. Committee on Oversight and Government Reform)